Celgene Corp. (CELG)

93.47
NASDAQ : Health Technology
Prev Close 98.91
Day Low/High 93.47 / 95.80
52 Wk Low/High 58.59 / 98.97
Avg Volume 6.64M
Exchange NASDAQ
Shares Outstanding 705.26M
Market Cap 69.76B
EPS 5.70
P/E Ratio 15.10
Div & Yield N.A. (N.A)
Celgene Chart Bears Watching

Celgene Chart Bears Watching

Although it appears the low may be in from October, it is hard to trust this stock.

Key Feature in Marketks

The key feature within the markets is the renewed and continued strength in pharma and biotech which started last week. Allergan , Celgene and Gilead Sciences  are upside features. I am not involved and I would not chase big Pharma or biotech.

Mid-Afternoon Observations

Some mid afternoon observations:   * Small yield flattening in today's session and little change in bond yields. * High yield is slipping a bit. * The U.S. Dollar is strengthening after morning weakness. * Oil down after weeks of strength (-$0.76/ba...

Here's What's Up This A.M.

The Nasdaq (QQQs) turn slightly negative as most of the FANGs reverse lower.   Retail, generics (Teva and Mylan ), big pharma (Merck and Bristol-Myers Squibb ) and biotech (Allergan , Gilead Sciences , Celgene ) are conspicuous to the downside.   Co...

The Market Tells a Tale of Two Gaps

The Market Tells a Tale of Two Gaps

Microsoft and Celgene both look like they want to fill a gap higher.

Big-Cap Biotechs Are Dragging

Biotech is conspicuously weak, with weakness in Allergan , Celgene and Gilead Sciences .   I suspect we could see tax selling in December, but it's still early.   Speculative biotech is not much better.   I am avoiding the sector for now.

Intermediate Trade: Celgene

Intermediate Trade: Celgene

I prefer a bullish trade on this stock.

Allergan's Drop Provides 10 Important Investing Lessons

Allergan's Drop Provides 10 Important Investing Lessons

On Thursday, I waved the white flag exited my AGN position.

Allergan's Ten Important Lessons

To me, there are a number of important lessons in Allergan's  $11 drop today:   There is no substitute for objective and hard-hitting security analysis. A variant view can be special and deliver alpha -- it can contribute importantly to avoiding los...

Potholes in the Market

Despite stocks near their all-time records, there are more potholes (this week) than observed on Second Avenue in the Upper East Side in New York City.  Today's potholes:  * Optical (Oclaro guidedown) * FANG (reaction to earnings) * Retail (again) *...

This Allergan Bull Reluctantly Waves the White Flag and Exits the Stock

This Allergan Bull Reluctantly Waves the White Flag and Exits the Stock

Looking ahead, Allergan may be more vulnerable than suggested by management or believed by analysts.

3 Bad News Buys: Celgene, Under Armour and General Electric

3 Bad News Buys: Celgene, Under Armour and General Electric

The very fact that contrarian investing is hard makes it an effective strategy since it is done by so few investors.

On Halloween, Here Are 5 Scary Stock Charts: Market Recon

On Halloween, Here Are 5 Scary Stock Charts: Market Recon

The fundamentals are there, supported by earnings. Let's look at the charts.

Cramer: We're Seeing the Best of Times and the Worst of Times at the Same Time

Cramer: We're Seeing the Best of Times and the Worst of Times at the Same Time

It depends on which aisle of the stock market you're on.

3 Small-Caps on My Growth Stock Radar

3 Small-Caps on My Growth Stock Radar

LGI Homes, ANI Pharmaceuticals and Sonus Networks are worth considering.

The Art and Science of Buying Dips

The Art and Science of Buying Dips

This can produce big gains, but what if the stock keeps dipping?

3 Biotech Stalwarts Just Can't Bio a Break

3 Biotech Stalwarts Just Can't Bio a Break

The stocks of Amgen, Celgene and Gilead Sciences all took hits after posting quarterly results.

There Is Sound Fundamental Reasoning Behind the Positivity: Market Recon

There Is Sound Fundamental Reasoning Behind the Positivity: Market Recon

The ECB's super dovish message was good for the markets.

Recently Merged DowDuPont Powers Dow Higher

Recently Merged DowDuPont Powers Dow Higher

Shares of DowDuPont jumped after issuing preliminary third-quarter results.

Two-Sided Market

An observation:  Despite being within 1% of the all-time high in the S&P Index, this week's feature was a number of investment potholes --relatively large sized individual fundamental disappointments followed by marked stock price drops. Celgene , B...

Cramer: Stock Market's 'Safety Dance' Has Reversed

Cramer: Stock Market's 'Safety Dance' Has Reversed

What was dangerous is now safe, what was safe is now risky.

Carpet Sweepers

A frequent theme of mine is the lack of follow-up and accountability by commentators and "talking heads" in the media of the many ideas that have soured.  Losers are part of the game -- and those who don't confess to mistakes are either lying or, as...

Video: Jim Cramer on Twitter, Comcast, Ford, Southwest Air, NXP and Celgene

Video: Jim Cramer on Twitter, Comcast, Ford, Southwest Air, NXP and Celgene

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Thursday's trending stocks.

Video: Jim Cramer: I Don't Want to Panic and Sell Celgene

Video: Jim Cramer: I Don't Want to Panic and Sell Celgene

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't advise panicking over Celgene.

Market Action Isn't So Hot Despite What You May Hear

Market Action Isn't So Hot Despite What You May Hear

Breadth is positive, but pockets of momentum are very limited.

Buying More Allergan on Biotech Weakness

This morning I added to Allergan on weakness in biotech -- a true contrarian and counterintuitive bet considering the struggles of Celgene et al. However, I am still only medium in size in my AGN position.

Celgene Falls After Updates to 2017 Guidance, 2020 Targets -- Biotech Movers

Celgene Falls After Updates to 2017 Guidance, 2020 Targets -- Biotech Movers

The Summit, N.J.-based firm on Oct. 26 unveiled third-quarter results and updated its 2017 outlook and financial targets for 2020.

Praise by Name, Criticize by Category

As an observation, I find -- and this is characteristic of a mature bull market -- that many investors, strategists, commentators and talking heads are just taking shots in the dark on stocks these days and are not adjusting their outlooks for chang...